Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT02159495 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Adult Acute Myeloid Leukemia in Remission
Acute Biphenotypic Leukemia
Early Relapse of Acute Myeloid Leukemia
Late Relapse of Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm
Acute Myeloid Leukemia
Adult Acute Lymphoblastic Leukemia
Interleukin-3 Receptor Subunit Alpha Positive
Minimal Residual Disease
Refractory Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions

DRUG: cyclophosphamide
BIOLOGICAL: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes
OTHER: laboratory biomarker analysis
BIOLOGICAL: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes
DRUG: Fludarabine Phosphate

Sponsor

City of Hope Medical Center

Collaborators

[object Object]
[object Object]